212 related articles for article (PubMed ID: 29479832)
41. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
[TBL] [Abstract][Full Text] [Related]
42. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
43. Bisphosphonates for the prevention and treatment of osteoporosis.
Maraka S; Kennel KA
BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
[TBL] [Abstract][Full Text] [Related]
44. [The effect of alcohol on bone mineral density in men].
Medraś M; Jankowska EA
Przegl Lek; 2000; 57(12):743-6. PubMed ID: 11398600
[TBL] [Abstract][Full Text] [Related]
45. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
Lems WF; Saag K
Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
[TBL] [Abstract][Full Text] [Related]
46. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
Reid IR
Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
[TBL] [Abstract][Full Text] [Related]
47. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
[TBL] [Abstract][Full Text] [Related]
48. Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation.
Ng TM; Bajjoka IE
Ann Pharmacother; 1999 Feb; 33(2):233-5. PubMed ID: 10084420
[TBL] [Abstract][Full Text] [Related]
49. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.
Compston JE
Gut; 1986 Sep; 27(9):1073-90. PubMed ID: 3530896
[No Abstract] [Full Text] [Related]
50. Extrahepatic manifestations of cholestasis.
Glasova H; Beuers U
J Gastroenterol Hepatol; 2002 Sep; 17(9):938-48. PubMed ID: 12167113
[TBL] [Abstract][Full Text] [Related]
51. Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Muschitz C; Kocijan R; Pahr D; Patsch JM; Amrein K; Misof BM; Kaider A; Resch H; Pietschmann P
Calcif Tissue Int; 2015 Jun; 96(6):477-89. PubMed ID: 25911186
[TBL] [Abstract][Full Text] [Related]
52. [Osteoporosis in the aged male].
Szulc P; Delmas PD
Presse Med; 2002 Nov; 31(37 Pt 1):1760-9. PubMed ID: 12489321
[TBL] [Abstract][Full Text] [Related]
53. Osteoporosis across chronic liver disease.
Guarino M; Loperto I; Camera S; Cossiga V; Di Somma C; Colao A; Caporaso N; Morisco F
Osteoporos Int; 2016 Jun; 27(6):1967-77. PubMed ID: 26846777
[TBL] [Abstract][Full Text] [Related]
54. Glucocorticoid-induced osteoporosis and its treatment.
Pennisi P; Trombetti A; Rizzoli R
Clin Orthop Relat Res; 2006 Feb; 443():39-47. PubMed ID: 16462424
[TBL] [Abstract][Full Text] [Related]
55. Osteoporosis after liver transplantation.
Compston JE
Liver Transpl; 2003 Apr; 9(4):321-30. PubMed ID: 12682881
[TBL] [Abstract][Full Text] [Related]
56. Osteomalacia, vitamin D deficiency and cholestasis in chronic liver disease.
Dibble JB; Sheridan P; Hampshire R; Hardy GJ; Losowsky MS
Q J Med; 1982; 51(201):89-103. PubMed ID: 6981120
[TBL] [Abstract][Full Text] [Related]
57. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.
Janes CH; Dickson ER; Okazaki R; Bonde S; McDonagh AF; Riggs BL
J Clin Invest; 1995 Jun; 95(6):2581-6. PubMed ID: 7769100
[TBL] [Abstract][Full Text] [Related]
58. Bisphosphonate therapy in children with secondary osteoporosis.
Papapoulos SE
Horm Res Paediatr; 2011; 76 Suppl 1():24-7. PubMed ID: 21778744
[TBL] [Abstract][Full Text] [Related]
59. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
60. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
